PURLs

When to “CAP” off treatment for pneumonia

Author and Disclosure Information

 

References

WHAT’S NEW

Clinical support for 2007 guidelines

This is the first study to clinically support the IDSA/ATS guidelines, which state that a 5-day course of antibiotic therapy for hospitalized adults with CAP is effective and without increased risk of adverse events.

CAVEATS

Generalizability to other meds and settings is unclear

This study focused on antibiotic duration for the treatment of CAP in hospitalized patients and mainly used quinolone antibiotics. It remains unclear if duration of therapy is as effective in the outpatient setting or when using alternative antibiotic regimens.

If patients continued to have symptoms (such as fever or low oxygen saturation on room air) after 5 days of antibiotic treatment, antibiotic treatment was continued in the study. Thus, patients in real life who continue to have symptoms may need individualized therapy and may require more than 5 days of antibiotics.

CHALLENGES TO IMPLEMENTATION

Antibiotics end before clinical improvement occurs

This study noted an average of 12 days in both groups for patients to achieve clinical improvement, with upwards of 15 to 18 days for patients to return to normal activity. Patients and providers may be dissatisfied if the treatment course ends days before clinical improvement of symptoms. This may cause prescribers to lengthen the duration of antibiotic therapy inappropriately.

ACKNOWLEDGEMENT

The PURLs Surveillance System was supported in part by Grant Number UL1RR024999 from the National Center For Research Resources, a Clinical Translational Science Award to the University of Chicago. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Research Resources or the National Institutes of Health.

Pages

Copyright © 2017. The Family Physicians Inquiries Network. All rights reserved.

Online-Only Materials

AttachmentSize
PDF icon JFP06610629_methodology353.93 KB

Recommended Reading

Tezepelumab reduces exacerbations in persistent, treatment-resistant asthma
MDedge Family Medicine
Hospital-led interventions cut pediatric asthma hospitalizations
MDedge Family Medicine
Riociguat may benefit subset of PAH patients
MDedge Family Medicine
Statins linked to lower death rates in COPD
MDedge Family Medicine
E-cigarettes most popular among youngest adults
MDedge Family Medicine
FDA approves triple-therapy inhaler for COPD
MDedge Family Medicine
With inpatient flu shots, providers’ attitude problem may outweigh parents’
MDedge Family Medicine
New AAP policy recommends flu vaccination regardless of egg allergy
MDedge Family Medicine
Clinicians: Be clear about flu vaccine’s value
MDedge Family Medicine
Insist on flu vaccination for all, say experts
MDedge Family Medicine